Characteristics of patients with seasonal allergic rhinitis and concomitant asthma

Bousquet, Jean; Boushey, Homer A.; Busse, William W.; Canonica, Giorgio Walter; Durham, Stephen R.; Irvin, Charles G.; Karpel, Jill P.; Cauwenberge, Paul Van; Chen, R; Iezzoni, Domenic G.; Harris, Alan G.

doi:10.1111/j.1365-2222.2004.01969.x

Cited by 48 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pollen-allergic patients commonly have rhinitis and conjunctivitis during the pollen season. They can also have pharyngitis, cough and wheezing (1940). In most patients, chest symptoms are not associated with a measurable airflow obstruction (1940)(1941)(1942).…”

Section: Common Risk Factorsmentioning

confidence: 99%

“…They can also have pharyngitis, cough and wheezing (1940). In most patients, chest symptoms are not associated with a measurable airflow obstruction (1940)(1941)(1942). Moreover, true asthma exacerbations may occur during dry days in some patients naturally exposed to pollens (1943,1944), probably because pollen allergens can be born by submicronic particles which can penetrate deeply into the airways (399).…”

Section: Common Risk Factorsmentioning

confidence: 99%

“…Rhinitis is an independent risk factor for both recurrent cough and wheezing during childhood and adulthood (2148)(2149)(2150). In patients with seasonal rhinitis, dry cough is common and often the predominant non-nasal symptom (1940).…”

Section: Chronic Coughmentioning

confidence: 99%

See 2 more Smart Citations

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

Self Cite

3,867

1,761

View full text Add to dashboard Cite

Section: Common Risk Factorsmentioning

confidence: 99%

Section: Common Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

Self Cite

3,867

1,761

View full text Add to dashboard Cite

“…Evidence that chronic allergen exposure caused by house dust mites (69) or pollens (70) can have the same effect is weaker possibly because chest symptoms in asthma may also be related to nasal symptoms (71). In experimental studies with asthmatic patients, a single, high-dose allergen challenge can easily reproduce most, if not all, features of an asthma exacerbation (72).…”

Section: Acute and Chronic Allergen Exposurementioning

confidence: 99%

Asthma control or severity: that is the question

Humbert

Holgate

Boulet

et al. 2007

Allergy

Self Cite

View full text Add to dashboard Cite

In the first National Heart Lung and Blood Institute and Global Initiative for Asthma (GINA) guidelines, the level of symptoms and airflow limitation and its variability allowed asthma to be subdivided by severity into four subcategories (intermittent, mild persistent, moderate persistent, and severe persistent). It is important to recognize, however, that asthma severity involves both the severity of the underlying disease and its responsiveness to treatment. Thus, the first update of the GINA guidelines defined asthma severity depending on the clinical features already proposed as well as the current treatment of the patient. In addition, severity is not a fixed feature of asthma, but may change over months or years, whereas the classification by severity suggests a static feature. Moreover, using severity as an outcome measure has limited value in predicting what treatment will be required and what the response to that treatment might be. Because of these considerations, the classification of asthma severity is no longer recommended as the basis for treatment decisions, a periodic assessment of asthma control being more relevant and useful.

show abstract

“…Studies indicate a strong relationship between asthma and AR [7][8][9], with ,20-50% patients with AR experiencing concomitant asthma [10]. A 23-yr follow-up study of college students in the USA showed that AR occurred in 86% of asthmatics [11], whereas a French study [12] that assessed the QoL in patients with AR and asthma found that 78% of asthmatics also suffered from AR.…”

mentioning

confidence: 99%

Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases

Bousquet¹,

Wahn²,

Meltzer³

et al. 2008

Eur Respir Rev

Self Cite

View full text Add to dashboard Cite

Immunoglobulin E (IgE) is central to the development of allergic diseases. Crosslinking of cell-bound IgE by the allergen leads to the initiation of the inflammatory cascade. Omalizumab, an anti-IgE antibody, forms complexes with free IgE, thereby inhibiting the allergic reaction before its commencement.A survey of the clinical trials performed on omalizumab indicated that this anti-IgE antibody is efficacious and well tolerated in the treatment of separate and concomitant asthma and rhinitis. In patients with poorly controlled asthma, omalizumab reduced the asthma exacerbation and emergency visit rate, along with improving the quality of life. The improvement in asthma control was associated with a reduction of inhaled and oral corticosteroids. Improved nasal symptom scores and a reduced need for antihistamines were observed in patients with allergic rhinitis. Omalizumab was also proven to be effective as an add-on therapy for concomitant asthma and rhinitis.In conclusion, omalizumab provides an integrated approach for the treatment and management of allergic respiratory diseases.

show abstract

Characteristics of patients with seasonal allergic rhinitis and concomitant asthma

Abstract: Patients with seasonal allergic rhinitis and concomitant asthma appear to differ from those with persistent asthma. A prospective study should be designed to discover whether patients with seasonal rhinitis and asthma may represent a distinct nosological entity, 'allergic airway disease'.

Cited by 48 publications

References 32 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Asthma control or severity: that is the question

Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases

Contact Info

Product

Resources

About